Search results for "Neoplastic"

showing 10 items of 2901 documents

Dual targeting of higher-order DNA structures by azacryptands induces DNA junction-mediated DNA damage in cancer cells

2021

Abstract DNA is intrinsically dynamic and folds transiently into alternative higher-order structures such as G-quadruplexes (G4s) and three-way DNA junctions (TWJs). G4s and TWJs can be stabilised by small molecules (ligands) that have high chemotherapeutic potential, either as standalone DNA damaging agents or combined in synthetic lethality strategies. While previous approaches have claimed to use ligands that specifically target either G4s or TWJs, we report here on a new approach in which ligands targeting both TWJs and G4s in vitro demonstrate cellular effects distinct from that of G4 ligands, and attributable to TWJ targeting. The DNA binding modes of these new, dual TWJ-/G4-ligands w…

AcademicSubjects/SCI00010DNA damage[SDV]Life Sciences [q-bio][CHIM.THER] Chemical Sciences/Medicinal ChemistryCellAntineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/CancerSynthetic lethality[CHIM.THER]Chemical Sciences/Medicinal ChemistryStructure-Activity Relationship03 medical and health scienceschemistry.chemical_compound0302 clinical medicineChemical Biology and Nucleic Acid Chemistry[SDV.CAN] Life Sciences [q-bio]/CancerNeoplasmsGeneticsmedicineHumans[CHIM]Chemical Sciences030304 developmental biology0303 health sciencesbiologyTopoisomeraseDNASmall moleculeIn vitroCell biologyG-Quadruplexesmedicine.anatomical_structurechemistry030220 oncology & carcinogenesisCancer cellMCF-7 Cellsbiology.proteinAzabicyclo CompoundsDNADNA Damage
researchProduct

An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma

2020

Introduction: Regimens involving intensive immuno-chemotherapy, followed by high-dose therapy and autologous stem cell transplant represent the standard treatment for younger fit patients with mantle cell lymphoma (MCL). Targeted approaches (i.e. ibrutinib, bortezomib, and lenalidomide) represent the backbone of therapy for relapsed cases. Areas covered: Acalabrutinib is a novel small molecule with a butynamide moiety specifically designed to irreversibly inhibit Bruton tyrosine kinase (BTK), which is more potent and selective than ibrutinib. Relevant publications have been identified through literature searches using the terms 'mantle cell lymphoma' and 'acalabrutinib'. Expert opinion: Aca…

Acalabrutinib; BTK; MCL; therapy; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Lymphoma Mantle-Cell; Protein Kinase Inhibitors; PyrazinesOncologymedicine.medical_specialtyLymphomaAntineoplastic AgentsLymphoma Mantle-Cell03 medical and health scienceschemistry.chemical_compound0302 clinical medicineimmune system diseaseshemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsAgammaglobulinaemia Tyrosine KinaseHumansMedicineBruton's tyrosine kinasePharmacology (medical)Protein Kinase InhibitorsLenalidomidePharmacologytherapy.therapybiologyAcalabrutinibbusiness.industryBortezomibStandard treatmentMCLGeneral MedicineMantle-Cellmedicine.diseaseClinical trialchemistryBTKPyrazines030220 oncology & carcinogenesisIbrutinibBenzamidesbiology.proteinAcalabrutinibMantle cell lymphomabusiness030217 neurology & neurosurgerymedicine.drugExpert Opinion on Pharmacotherapy
researchProduct

Acetogenins from Annonaceae: Recent Progress in Isolation, Synthesis and Mechanisms of Action

2005

Covering: the literature from 1998 to 2004 The aim of the present review is to summarise the knowledge about newly isolated acetogenins (ACGs) in the last six years. It will also report the total syntheses that have allowed either the confirmation or the revision of some structures, together with the biological activities and mechanism of action of such interesting natural products. In fact, of the 417 isolated compounds reviewed, over 176 have been added during the period from 1998 to 2004.

AcetogeninsIsolation (health care)StereochemistryAnnonacinAnnonaceaeComputational biologyBiochemistryLactoneschemistry.chemical_compoundDrug DiscoverymedicineMolecular StructureTraditional medicinebiologyChemistryOrganic ChemistryGeneral Medicinebiology.organism_classificationAntineoplastic Agents PhytogenicAction (philosophy)Mechanism of actionAnnonaceaeAcetogeninFatty AlcoholsAnnonaceous Acetogeninsmedicine.symptomBullatacinChemInform
researchProduct

Cladosins L-O, new hybrid polyketides from the endophytic fungus Cladosporium sphaerospermum WBS017

2019

Abstract The endophytic fungus Cladosporium sphaerospermum WBS017 was obtained from healthy bulbs of Fritillaria unibracteata var. wabuensis. Fermentation of C. sphaerospermum on solid rice medium yielded three new hybrid polyketides, cladosins L−N (1–3), and a known derivative cladodionen (4). Further cultivation of this fungus on white bean medium afforded an additional new hybrid polyketide, cladosin O (5) along with three known analogues (6–8). The structures of the new compounds were elucidated using a combination of NMR and HRESIMS data. The absolute configurations of compounds 2 and 3 were determined by Mosher’s method and TDDFT-ECD calculations. All isolated compounds were evaluated…

Acinetobacter baumanniiStaphylococcus aureusAntifungal AgentsUstilagoStereochemistryAntineoplastic AgentsMicrobial Sensitivity TestsSaccharomyces cerevisiaeFungusmedicine.disease_cause01 natural sciencesMiceStructure-Activity Relationship03 medical and health sciencesPolyketideCell Line TumorDrug DiscoveryEnterococcus faecalisUstilagomedicineAnimalsDensity Functional TheoryCell Proliferation030304 developmental biologyPharmacology0303 health sciencesDose-Response Relationship DrugMolecular Structurebiology010405 organic chemistryChemistryOrganic ChemistryFritillaria unibracteataMycobacterium tuberculosisGeneral Medicinebiology.organism_classificationAntimicrobialAnti-Bacterial Agents0104 chemical sciencesStaphylococcus aureusPolyketidesPseudomonas aeruginosaFermentationDrug Screening Assays AntitumorAntibacterial activityCladosporiumEuropean Journal of Medicinal Chemistry
researchProduct

Biology and management of therapy-related acute promyelocytic leukemia.

2013

Therapy-related acute promyelocytic leukemia (t-APL) has been increasingly reported after exposure to cytotoxic and/or immunosuppressive agents given for prior malignancies or autoimmune diseases. t-APL represents both a model for better understanding human leukemogenesis and an interesting therapeutic subset which requires specific adaptations for optimal management.We discuss here potential risk factors for t-APL development and the main biologic and clinical characteristics of t-APL as compared to de-novo APL.In addition, we review therapeutic results obtained in patients with t-APL receiving conventional retinoic acid and chemotherapy and discuss new treatment opportunities with minimal…

Acute promyelocytic leukemiaAdultMaleCancer ResearchRetinoic acidAntineoplastic AgentsTretinoinAcuteArsenicalschemistry.chemical_compoundArsenic TrioxideLeukemia Promyelocytic Acuteimmune system diseasesRisk FactorsNeoplasmsCytotoxic T cellMedicineHumansArsenic trioxideneoplasmsAdult; Antineoplastic Agents; Arsenicals; Early Diagnosis; Female; Humans; Leukemia Promyelocytic Acute; Male; Middle Aged; Neoplasms Second Primary; Oxides; Retrospective Studies; Risk Factors; TretinoinRetrospective StudiesPromyelocyticTherapy relatedLeukemiabusiness.industryNeoplasms Second PrimaryOxidesMiddle Agedmedicine.diseaseSecond PrimaryEarly DiagnosisOncologychemistryCancer researchFemalebusinessSettore MED/15 - Malattie del SangueCurrent opinion in oncology
researchProduct

Therapy-Related Myeloid Neoplasms in Patients With Acute Promyelocytic Leukemia Treated With All-Trans-Retinoic Acid and Anthracycline-Based Chemothe…

2010

Purpose We analyzed the incidence, risk factors, and outcome of therapy-related myeloid neoplasms (t-MNs) in patients with acute promyelocytic leukemia (APL) in first complete remission (CR). Patients and Methods From 1996 to 2008, 1,025 patients with APL were enrolled onto three sequential trials (LPA96, LPA99, and LPA2005) of the Programa Español para el Tratamiento de Enfermedades Hematológicas and received induction and consolidation therapy with all-trans-retinoic acid (ATRA) and anthracycline-based chemotherapy. Results Seventeen of 918 patients who achieved CR developed t-MN (10 with < 20% and seven with ≥ 20% of bone marrow blasts) after a median of 43 months from CR. Partial and…

Acute promyelocytic leukemiaAdultMaleCancer Researchmedicine.medical_specialtyMyeloidAnthracyclinemedicine.medical_treatmentTretinoinGastroenterologyLeukemia Promyelocytic AcuteTretinoinRisk FactorsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansCumulative incidenceAnthracyclinesProspective StudiesAgedChemotherapybusiness.industryIncidenceNeoplasms Second PrimaryMiddle Agedmedicine.diseasePrognosisSurgeryLeukemiamedicine.anatomical_structureTreatment OutcomeOncologyFemaleBone marrowbusinessBone Marrow Neoplasmsmedicine.drugJournal of Clinical Oncology
researchProduct

First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic…

2017

Recently, studies in adults with acute promyelocytic leukemia (APL) showed high cure rates in low-risk patients treated with all-trans retinoid acid (ATRA) and arsenic trioxide (ATO), while toxicities were significantly reduced compared to the standard treatment with ATRA and chemotherapy. Here we report about first experience with 11 pediatric patients with low-risk APL treated with ATRA and ATO. All patients stayed in molecular remission. All suffered from hyperleukocytosis. Two patients experienced reversible severe side effects. One suffered from osteonecroses at both femurs, seizures, as well as posterior reversible encephalopathy syndrome, the other patient had an abducens paresis.

Acute promyelocytic leukemiaMalemedicine.medical_specialtyAdolescentmedicine.drug_classmedicine.medical_treatmentMedizinTretinoinGastroenterologyArsenicals03 medical and health scienceschemistry.chemical_compound0302 clinical medicineArsenic TrioxideLeukemia Promyelocytic AcuteTretinoinInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansRetinoidArsenic trioxideChildneoplasmsParesisRetrospective StudiesChemotherapybusiness.industryStandard treatmentInfantPosterior reversible encephalopathy syndromeOxidesHematologymedicine.diseaseSurgeryTreatment OutcomeOncologychemistry030220 oncology & carcinogenesisChild PreschoolPediatrics Perinatology and Child HealthFemalemedicine.symptombusiness030215 immunologymedicine.drug
researchProduct

TP53 and p16INK4A, but not H-KI-Ras, are involved in tumorigenesis and progression of pleomorphic adenomas.

2006

The putative role of TP53 and p16INK4A tumor suppressor genes and Ras oncogenes in the development and progression of salivary gland neoplasias was studied in 28 cases of pleomorphic adenomas (PA), 4 cases of cystic adenocarcinomas, and 1 case of carcinoma ex-PA. Genetic and epigenetic alterations in the above genes were analyzed by Polymerase Chain Reaction/Single Strand Conformational Polymorphism (PCR/SSCP) and sequencing and by Methylation Specific-PCR (MS-PCR). Mutations in TP53 were found in 14% (4/28) of PAs and in 60% (3/5) of carcinomas. Mutations in H-Ras and K-Ras were identified in4%(1/28) and7% (2/28) of PAs, respectively. Only 20% (1/5) of carcinomas screened displayed mutatio…

AdenomaAdenomaGenotypePhysiologyClinical BiochemistryBiologymedicine.disease_causeMethylationEpigenesis GeneticProto-Oncogene Proteins p21(ras)GenotypemedicineCarcinomaHumansEpigeneticsTP53GeneCyclin-Dependent Kinase Inhibitor p16Base SequenceSingle-strand conformation polymorphismCell BiologyMethylationmedicine.diseaseMolecular biologyCell Transformation NeoplasticMutationDisease ProgressionTumor Suppressor Protein p53Carcinogenesis
researchProduct

Pituispheres Contain Genetic Variants Characteristic to Pituitary Adenoma Tumor Tissue

2020

The most common type of pituitary neoplasms is benign pituitary adenoma (PA). Clinically significant PAs affect around 0.1% of the population. Currently, there is no established human PA cell culture available and when PA tumor cells are cultured they form two distinct types depending on culturing conditions either free-floating aggregates also known as pituispheres or cells adhering to the surface of cell plates and displaying mesenchymal stem-like properties. The aim of this study was to trace the origin of sphere-forming and adherent pituitary cell cultures and characterize the potential use of these surgery derived cell lines as PA model. We carried out a paired-end exome sequencing of …

AdenomaAdult0301 basic medicinetumor sequencingSomatic cellEndocrinology Diabetes and MetabolismPopulationCell030209 endocrinology & metabolismpituitary adenomaPituitary neoplasmBiologylcsh:Diseases of the endocrine glands. Clinical endocrinologyGermlinewhole exome sequencing03 medical and health sciences0302 clinical medicineEndocrinologyBiomarkers TumorTumor Cells CulturedmedicineHumansExomePituitary NeoplasmseducationExome sequencingOriginal Researcheducation.field_of_studylcsh:RC648-665Mesenchymal stem cellpituitary adenoma culturesMiddle AgedPrognosisMolecular biologyGene Expression Regulation Neoplastic030104 developmental biologymedicine.anatomical_structureCell culturePituitary GlandMutationpituispheresFollow-Up StudiesFrontiers in Endocrinology
researchProduct

Endoscopic therapy of adenomas of the papilla of Vater. A retrospective analysis with long-term follow-up.

2001

Abstract Aims. To compare the efficacy and the complication rate between endoscopic snare resection of adenomas of Vater's papilla and endoscopic palliation. Methods. In a retrospective, non randomized manner, we compared long-term results of our endoscopic strategies in 36 patients with histologically confirmed adenoma of Vater's papilla submitted either to local endoscopic snare resection (n=18) or to simple endoscopic palliation (n=18), respectively. Results. Between 1985 and 1998 results were reviewed. Median age was 76.5 (range 42–89) years in the palliation, and 64.0(23–89) years in the endoscopic snare resection group. Median duration of follow-up was 33 (6–135) and 75.0 (27–123) mon…

AdenomaAdultMalemedicine.medical_specialtyAmpulla of VaterAdenomamedicine.medical_treatmentCommon Bile Duct NeoplasmsAdenocarcinomaProsthesisMcNemar's testmedicineHumansAgedRetrospective StudiesAged 80 and overHepatologybusiness.industryMortality rateIncidence (epidemiology)GastroenterologyRetrospective cohort studyEndoscopyMiddle Agedmedicine.diseaseSurvival Analysisdigestive system diseasesSurgeryMajor duodenal papillaCell Transformation NeoplasticTreatment OutcomeAdenocarcinomaFemalebusinessDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct